Objective: To systematically review and meta-analyze published data about the diagnostic performance of Fluorine-18-Fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) and PET/computed tomography (PET/CT) in patients with chronic inflammatory bowel disease (IBD). Methods: A comprehensive computer literature search of studies published through May 2012 regarding 18 F-FDG-PET and PET/CT in patients with IBD was performed. All retrieved studies were reviewed and qualitatively analyzed. Pooled sensitivity, specificity, positive and negative likelihood ratio (LR + and LR −) and diagnostic odd ratio (DOR) of 18 F-FDG PET and PET/CT in patients with IBD on a per segment-based analysis were calculated. The area under the ROC curve was calculated to measure the accuracy of 18 F-FDG PET and PET/CT in patients with IBD.
Results: Nineteen studies comprising 454 patients with suspected IBD were included in the qualitative analysis (systematic review) and discussed. The quantitative analysis (meta-analysis) of seven selected studies (including 219 patients with IBD) provided the following results on a per segment-based analysis: sensitivity was 85% [95% confidence interval (95%CI) 81-88%], specificity 87% (95%CI 84-90%), LR+ 6.19 (95%CI: 2.86-13.41), LR− 0.19 (95%CI: 0.10-0.34), and DOR 44.35 (95%CI: 11.77-167.07). The area under the ROC curve was 0.933.
Introduction
The diagnosis of chronic inflammatory bowel disease (IBD) is usually performed by a combination of data obtained by a detailed patient history, physical examination, laboratory tests, radiologic studies (including CT, magnetic resonance imaging [MRI] , ultrasonography [US]), and endoscopic evaluation. 1, 2 A challenge for the clinicians in managing IBD is determining whether symptoms are related to the inflammation in the intestinal tract. Therefore, a noninvasive test able to detect active inflammation in the intestinal tract may be useful in the evaluation and management of IBD. 2, 3 Fluorine-18-Fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) and PET/computed tomography (PET/CT) have been proposed as noninvasive imaging methods to assess extent, location, and disease activity in patients with IBD. 18 F-FDG PET allows the identification of areas of increased metabolic activity by measuring the uptake of 18 F-FDG, a glucose analogue, both in inflammatory diseases and in malignancies. In fact, not only neoplastic cells but also inflammatory cells, such as neutrophils and macrophages, may accumulate high levels of 18 F-FDG. 2, 4, 5 Moreover, hybrid PET/CT device allows enhanced detection and characterization of abnormal intestinal findings, by combining the functional data obtained from 18 F-FDG PET with morphological data obtained from CT. 6, 7 Several studies have evaluated 18 F-FDG PET and PET/CT in assessing IBD, reporting different values of sensitivity and specificity in this setting. The purpose of our study is to systematically review and meta-analyze published data on the diagnostic performance of 18 F-FDG PET or PET/CT in patients with suspected IBD.
Methods
Our meta-analysis was performed according to the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) statement which describes an evidence-based minimum set of items for reporting in systematic reviews and meta-analyses. 8 
Search strategy
A comprehensive computer literature search of the PubMed/ MEDLINE, Embase and Scopus databases was conducted to find relevant published articles on the diagnostic performance of 18 F-FDG-PET and PET/CT in patients with IBD. We used a search algorithm that was based on a combination of the terms: a) "PET" OR "positron emission tomography" AND b) "IBD" or "inflammatory bowel disease" or "Crohn" or "ulcerative colitis". No beginning date limit was used; the search was updated until May 31st, 2012. No language restriction was used. To expand our search, references of the retrieved articles were also screened for additional studies.
Study selection
Studies or subsets in studies investigating the diagnostic performance of 18 F-FDG PET or PET/CT in patients with IBD were eligible for inclusion. The exclusion criteria were: a) articles not within the field of interest of this review; b) review articles, editorials or letters, comments, conference proceedings; c) case reports or small case series; d) overlap in patient data (duplicate publication; in such cases the most complete article was included).
For the quantitative analysis (meta-analysis) we also excluded studies with insufficient data to reassess sensitivity or specificity.
Three researchers (GT, NQ and AC) independently reviewed the titles and abstracts of the retrieved articles, applying the inclusion and exclusion criteria mentioned above. Articles were rejected if they were clearly ineligible. The same three researchers then independently reviewed the full-text version of the remaining articles to determine their eligibility for inclusion. Disagreements were resolved in a consensus meeting.
Data extraction
For each included study, information was collected concerning basic study (authors, year of publication, country of origin, study design), patient characteristics (mean age, sex, number of patients with IBD, type of IBD), technical aspects (device used, radiopharmaceutical injected dose, time between 
Quality assessment
The 2011 Oxford Center for Evidence-Based Medicine checklist for diagnostic studies was used for quality assessment of the included studies. 9 This checklist has 5 major parts as follows: 
Statistical analysis
Sensitivity and specificity, positive and negative likelihood ratio (LR + and LR −) and diagnostic odd ratio (DOR) of 18 F-FDG PET and PET/CT in patients with IBD was obtained from individual studies on a per segment-based analysis. A random effect model was used for statistical pooling of the data. Pooled data were presented with 95% confidence intervals (95%CI). A I-square index was used to test for heterogeneity between studies. The area under the ROC curve was calculated to measure the accuracy of 18 F-FDG PET or PET/CT in patients with IBD. For publication bias evaluation, funnel plots were used. Statistical analyses were performed using Meta-DiSc statistical software version 1.4 (Unit of Clinical Biostatistics, Ramón y Cajal Hospital, Madrid, Spain). 10 
Results

Literature search
The comprehensive computer literature search from PubMed/MEDLINE, Embase and Scopus databases revealed 104 articles. Reviewing titles and abstracts, 85 articles were excluded: 46 because not in the field of interest of this review, 26 as reviews or editorials, and 13 as case reports. Nineteen articles were selected and retrieved in full-text version [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] ; no additional study was found screening the references of these articles. From these 19 articles (including 454 patients with IBD) eligible for the qualitative analysis (systematic review), after reviewing the full-text article, 12 articles were excluded from the quantitative analysis (meta-analysis) due to insufficient data to calculate sensitivity or specificity of 18 F-FDG PET and PET/CT on a per segment-based analysis. 11, 14, 16, [18] [19] [20] [21] [22] [23] [24] 26, 28 Finally, seven studies, comprising a total sample size of 219 patients with suspected IBD met all inclusion and exclusion criteria, and they were included in our meta-analysis ( Fig. 1) . 12, 13, 15, 17, 25, 27, 29 The characteristics of the included studies are presented in Tables 1-2. 
Qualitative analysis (systematic review)
Using the database search, 19 complete articles written over the past 15 years were found; most of them were prospective studies. Fifteen studies evaluated adult patients, 11, 13, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] 28, 29 whereas the remaining four articles included pediatric patients (Table 1) . 12, 14, 15, 27 Thirteen studies used hybrid PET/CT device to evaluate patients with IBD, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] whereas six studies used PET imaging alone. [11] [12] [13] [14] [15] 29 Nevertheless, heterogeneous technical aspects between the included studies were found ( Table 2) .
The PET image analysis was usually performed by using qualitative and semi-quantitative criteria, the latter based on the calculation of standardized uptake values (SUV) of the bowel segments. Furthermore, the images were often analyzed using a 4-point scale taking the liver activity as a reference. A score of 0 corresponded to an activity of the bowel segment lower than the liver, 1 was equal to the liver, 2 and 3 were more active than the liver and considered as positive for active inflammation by most of the authors. Some authors compared the radiopharmaceutical uptake in the bowel segments to the spine (as reference region). 12, 14 The reference standard used and the other imaging modalities performed in the included studies were quite different (Tables 2 and 3) . Table 3 shows the results of the quality assessment of the studies included in this systematic review. 18 F-FDG PET and PET/CT demonstrated to be noninvasive tools for the assessment of patients with IBD 11-29 also if there is still limited evidence on these imaging methods in IBD. There may be a role for 18 F-FDG PET and PET/CT in the initial evaluation of adult patients with suspected IBD. In fact, these methods could be used to identify patients with a chronic intestinal inflammation in association with clinical history, physical examination, laboratory tests, other imaging modalities and endoscopic evaluation. 2, 18, 21, 24, 26, 28 In particular, 18 F-FDG PET and PET/CT may be useful when endoscopic evaluation may not be feasible (for example in some cases severe disease or strictures in the bowel may prevent a complete endoscopic examination). 2, 20, 28 In patients with an established diagnosis of IBD, 18 F-FDG PET and PET/CT may provide information about disease activity, location and extent within the intestinal tract, allowing early recognition of disease relapse and possible complications of the disease in association with clinical symptoms, physical exam and laboratory data. 2, 13, 16, 17, 19, 20, [22] [23] [24] [25] [26] 28, 29 As demonstrated by some studies, integrating 18 F-FDG PET with CT enterography 21, [23] [24] [25] or CT enteroclysis 18 may allow metabolic and morphologic assessment of disease activity.
Furthermore, the diagnostic accuracy of 18 F-FDG PET in the assessment of IBD was superior compared to hydro-MRI 13, 29 and granulocyte scintigraphy with labeled antibodies. 13 18 F-FDG PET and PET/CT may guide decisions regarding the choice of therapy. 26 These methods may be useful in identifying preoperatively the presence or absence of significant inflammation within the wall of an obstructive bowel segment. 20 Functional methods may also allow the evaluation of efficacy of the medical therapy in IBD, because metabolic changes after the treatment (assessed by 18 F-FDG PET) usually precede morphological changes (assessed by conventional imaging methods). 22 Several studies demonstrated that 18 F-FDG PET may be a useful noninvasive tool for identifying and localizing active intestinal inflammation also in children with IBD. Also if PET may not be able to replace conventional studies, several authors underlined that this functional method may be useful when conventional studies cannot be performed or fail to be completed. The role of 18 F-FDG PET and PET/CT in the assessment of IBD is promising but currently these diagnostic methods are routinely used in patients with IBD only in centers with a strong research presence in this area. 3 Whether the information derived from PET imaging justifies the additional radiation exposure related to the radiopharmaceutical administration requires additional investigation. 3 Furthermore, larger clinical trials and cost-effectiveness studies about the use of 18 F-FDG PET and PET/CT in patients with IBD are needed to strengthen the usefulness of these functional imaging methods in this setting. Similarly, it is conceivable that further developments of molecular imaging such as hybrid PET/MRI will provide relevant information on IBD. 30 
Quantitative analysis (meta-analysis)
The diagnostic performance results of 18 F-FDG PET and PET/CT in the seven included studies in the meta-analysis are presented in Figs. 2-4 .
The sensitivity of 18 F-FDG PET and PET/CT in detecting IBD calculated on a per segment-based analysis ranged from 70% to 100%, with pooled estimate of 85% (95%CI: 81-88%) (Fig. 2) . The included studies were statistically heterogeneous in their estimate of sensitivity (I-square: 79.7%).
The specificity of 18 F-FDG PET or PET/CT in detecting IBD calculated on a per segment-based analysis ranged from 55% to 97%, with pooled estimate of 87% (95%CI: 84-90%) (Fig. 3) . The included studies were statistically heterogeneous in their estimate of specificity (I-square: 91.6%).
The pooled LR+, LR− and DOR were 6.19 (95%CI: 2.86-13.41), 0.19 (95%CI: 0.10-0.34), and 44.35 (95%CI: 11.77-167.07), respectively. The area under the ROC curve was 0.933 (Fig. 4) . There was not statistically significant threshold effect in our study. Funnel plots of the included studies for sensitivity and specificity showed some asymmetry demonstrating a possible publication bias.
Discussion
To the best of our knowledge, this systematic review and meta-analysis is the first to evaluate the diagnostic performance of 18 F-FDG PET or PET/CT in patients with IBD. Several studies have used 18 F-FDG PET or PET/CT in patients with suspected IBD reporting different values of sensitivity and specificity. However, many of these studies have limited power, analyzing only relatively small numbers of patients. In order to derive more robust estimates of diagnostic performance of 18 F-FDG PET or PET/CT in patients with IBD we pooled published studies. A systematic review process was adopted in ascertaining studies, thereby avoiding selection bias. Furthermore, the quality of the included studies was assessed by using the 2011 Oxford Center for Evidence-Based Medicine checklist for diagnostic studies (Table 3) . 9 Pooled results of our meta-analysis indicate that 18 F-FDG PET and PET/CT demonstrate good sensitivity (85%) and good specificity (87%) in assessing IBD on a per segment-based analysis. Furthermore, the area under the ROC curve (0.933) demonstrates that 18 F-FDG PET and PET/CT are accurate diagnostic methods in this setting.
Nevertheless, only seven studies are included in the quantitative analysis and this could limit the statistical power of our meta-analysis.
Heterogeneity between studies may represent a potential source of bias. The included studies were statistically heterogeneous in their estimates of sensitivity and specificity. This heterogeneity is likely to arise through diversity in methodological aspects between different studies ( Table 2) . The baseline differences among the patients in the included studies (Table 1) and the study quality (Table 3) may have contributed to the observed heterogeneity of the results too. However, such variability was accounted for in a random effect model in our pooled analysis.
A limitation of our analysis is the lack of the calculation of pooled sensitivity and specificity of 18 F-FDG PET and PET/CT in different forms of IBD, for example CD vs. UC; the frequent mixing of these forms of IBD in the patient population of the included studies hampered the data extraction and the separate calculation of diagnostic performance of 18 F-FDG PET and PET/CT in such groups.
In our meta-analysis, we chose to calculate pooled sensitivity and specificity on a per segment-based analysis because most of the authors have adopted this criterion. However, we cannot exclude the potential bias derived from this choice, but there were not sufficient data to obtain significant results performing a per patient-or a per region-based pooled analysis. Furthermore, it was not possible to perform a sub-analysis comparing PET versus PET/CT results because of insufficient data.
Publication bias is a major concern in all meta-analyses as studies reporting significant findings are more likely to be published than those reporting nonsignificant results. Indeed, it is not unusual for small-sized early studies to report a positive relationship that subsequent larger studies fail to replicate. We assessed the publication bias in our analysis by using funnel plots which showed some asymmetry, especially for specificity pooling.
Conclusions
In patients with suspected IBD 18 F-FDG PET and PET/CT demonstrated good sensitivity and specificity. 18 F-FDG PET and PET/CT are accurate methods in this setting. Currently, the literature focusing on the use of 18 F-FDG PET or PET/CT in IBD remains still limited; thus, further large multicenter studies will be necessary to substantiate the diagnostic accuracy of 18 F-FDG PET and PET/CT in patients with IBD.
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